Press releases

Oxford Biomedica notes Axovant's six-month update from first cohort of Sunrise-PD Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson’s disease

Oxford, UK – 6 June 2019: Oxford Biomedica plc (LSE: OXB), a leading gene and cell therapy group, notes Axovant’s six-month update from first cohort of the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson’s disease.
 
Axovant reported six-month follow-up data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease. AXO-Lenti-PD was observed to be generally well tolerated, with no serious adverse events related to the product or the procedure and patients showed continued improvement from baseline across multiple measurements.

The first patient in the second cohort of the SUNRISE-PD clinical study was dosed in April 2019 and Axovant expects initial three-month data in the fourth quarter of 2019.

To view the full announcement from Axovant, please follow this link.

 

 -Ends-

 

Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Office  |  T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer  |  T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate Development & IR  |  T: +44 (0)1865 954 161 / E: ir@oxb.com  
Sarah MacLeod, Head of Communications  |  T: +44 (0)7747 602 739 / E: media@oxb.com

Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal  |  T: +44 (0)20 3709 5700

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com

About Axovant
Axovant, part of the Roivant family of companies, is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurological and neuromuscular diseases. The company’s current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com.

About Roivant
Roivant Sciences aims to improve health by rapidly delivering innovative medicines and technologies to patients. It does this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. For more information, please visit www.roivant.com.